BioAtla, traded as BCAB on NASDAQ, is facing a review for potential delisting, although it is unclear if the company will be suspended or remain listed during this process. The company has announced a share consolidation and its CFO has logged non-sale share withholdings for tax purposes. Additionally, there are concerns about BioAtla's cash burn situation, with some outlets providing stock price predictions and analyzing the company's financial situation.